Allogeneic cell replacement therapy for metabolic diseases
iPSC-derived cell replacement therapy for insulin dependent diabetes imbedded inside a therapeutic device implanted on the omentum
Focusing on the development of HSF1 inhibitor for the hormone treatment resistant prostate cancer.
Initial effort is an antibody-TGFβAntagonist-conjugate (ATAC) selectively blocking the TGFβ-related immune suppressive signaling in the immune cells for cancer treatment
Synthis Therapeutics, Inc.
MK2 allosteric inhibition
Reduce glucagon signalling by downstream kinase inhibition (PCC stage)
Founded in 2014, the company focuses on the research and development of new drugs related to skin diseases. Its product lines include small molecule new drugs for external use to treat hair loss (TDM-105795), new drugs for external use to treat psoriasis, and other product lines include drugs for treating dermatitis and other skin diseases.
Telo Therapeutics, Inc. is developing a novel, personalized medicine therapeutic to selectively inhibit cancer cell immortality.
Telo Therapeutics, Inc.
Biotechnology platform for innovative antibody drug development
Focus on discovery and R&D of new antibody drugs, searching for the natural antibodies from creatures to obtain valuable antibody drugs after screening and modification. The company has created a "primary tumour RNA sequence database" with proprietary intellectual property rights and obtained high licensing returns.
Small molecule drugs for cardiovascular diseases
A structure-based drug design project, which aims to produce small molecule drug to replace expensive antibody treatments